# Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients

Source: https://onco.cc/trials/nct01204125/  
OnCo record `nct01204125` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Paclitaxel / nab-paclitaxel and Iniparib in Breast cancer, run by Sanofi, completed.

## Summary

Two Regimens of SAR240550/Weekly Paclitaxel and Paclitaxel Alone as Neoadjuvant Therapy in Triple Negative Breast Cancer Patients is a phase 2 interventional study registered as NCT01204125 by Sanofi, with 141 participants recorded, started 2010-09 and reaching its primary completion in 2012-10. Interventions recorded: paclitaxel, Iniparib (SAR2405550 -BSI-201). Conditions recorded: Breast Cancer Female.

Linked to the drug Iniparib because the registry names it among its interventions and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01204125
- Phase: 2
- Setting: Randomized, Open-label, Phase 2 Study of the Efficacy and Safety of Weekly Paclitaxel Single-agent and Two Different Regimens of the PARP-1 Inhibitor SAR240550 (BSI-201) in Combination With Weekly Paclitaxel, as Neoadjuvant Therapy in Patients With Stage II-IIIA Triple Negative Breast Cancer (TNBC)
- Sponsor: Sanofi
- Enrolled: 141

## Sources

- ClinicalTrials.gov NCT01204125: https://clinicaltrials.gov/study/NCT01204125

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [Iniparib](https://onco.cc/drugs/iniparib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Sanofi](https://onco.cc/companies/sanofi/)

---
JSON: https://onco.cc/api/v1/entities/nct01204125.json